Open AccessPoly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
Author(s) -
Erin Hinchcliff,
Shan N. Westin,
Graziela Dal Molin,
Christopher J. Lafargue,
Robert L. Coleman
Publication year - 2019
Publication title -
international journal of gynecological cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.901
H-Index - 87
eISSN - 1525-1438
pISSN - 1048-891X
DOI - 10.1136/ijgc-2019-000499
Subject(s) - medicine , poly adp ribose polymerase , parp inhibitor , polymerase , ovarian cancer , food and drug administration , cancer research , cancer , drug , pharmacology , enzyme , biology , biochemistry
The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key evidence for their use and therapeutic indications. Furthermore, we provide an overview of the development of PARPi resistance and the emerging role of PARPi combination therapies, including those with anti-angiogenic and immunotherapeutic agents.